EP3846816A4 - Agents neuroprotecteurs pour le traitement de maladies neurodégénératives - Google Patents
Agents neuroprotecteurs pour le traitement de maladies neurodégénératives Download PDFInfo
- Publication number
- EP3846816A4 EP3846816A4 EP19858466.6A EP19858466A EP3846816A4 EP 3846816 A4 EP3846816 A4 EP 3846816A4 EP 19858466 A EP19858466 A EP 19858466A EP 3846816 A4 EP3846816 A4 EP 3846816A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- neurodegenerative diseases
- neuroprotective agents
- neuroprotective
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 239000004090 neuroprotective agent Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/124,974 US10874669B2 (en) | 2012-11-29 | 2018-09-07 | Neuroprotective agents for treatment of neurodegenerative diseases |
US16/154,301 US20190038622A1 (en) | 2012-11-29 | 2018-10-08 | Neuroprotective agents for treatment of neurodegenerative diseases |
PCT/US2019/049927 WO2020051435A1 (fr) | 2018-09-07 | 2019-09-06 | Agents neuroprotecteurs pour le traitement de maladies neurodégénératives |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3846816A1 EP3846816A1 (fr) | 2021-07-14 |
EP3846816A4 true EP3846816A4 (fr) | 2022-08-17 |
Family
ID=69723262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19858466.6A Pending EP3846816A4 (fr) | 2018-09-07 | 2019-09-06 | Agents neuroprotecteurs pour le traitement de maladies neurodégénératives |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3846816A4 (fr) |
CA (1) | CA3111561A1 (fr) |
WO (1) | WO2020051435A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115724758A (zh) * | 2021-08-24 | 2023-03-03 | 杭州中美华东制药有限公司 | 喜树碱衍生物中间体及其合成方法和利用中间体合成喜树碱衍生物的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014085600A1 (fr) * | 2012-11-29 | 2014-06-05 | Wayne State University | Agents neuroprotecteurs pour le traitement de maladies neurodégénératives |
-
2019
- 2019-09-06 WO PCT/US2019/049927 patent/WO2020051435A1/fr unknown
- 2019-09-06 CA CA3111561A patent/CA3111561A1/fr active Pending
- 2019-09-06 EP EP19858466.6A patent/EP3846816A4/fr active Pending
Non-Patent Citations (1)
Title |
---|
No further relevant documents disclosed * |
Also Published As
Publication number | Publication date |
---|---|
CA3111561A1 (fr) | 2020-03-12 |
EP3846816A1 (fr) | 2021-07-14 |
WO2020051435A1 (fr) | 2020-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288523A (en) | Compounds for the treatment of pd-l1 diseases | |
EP3621973A4 (fr) | Composés pour la prévention et le traitement de maladies et leur utilisation | |
EP3448851B8 (fr) | Composés de pyrazole di-substitués pour le traitement de maladies | |
EP4045036A4 (fr) | Amides hétéroaryle-biphényle pour le traitement de maladies associées à pd-l1 | |
EP3773629A4 (fr) | Thérapies à base de car-treg pour le traitement de maladies neurodégénératives | |
EP3600286A4 (fr) | Composés et procédés pour le traitement de maladies parasitaires | |
EP4045037A4 (fr) | Hétéroaryl-biphénylamines pour le traitement de maladies pd-l1 | |
EP3856243A4 (fr) | Méthodes de traitement de maladies neurodégénératives | |
EP3805216A4 (fr) | Composés pour le traitement ou la prévention de maladies hépatiques | |
EP3573617A4 (fr) | Agent thérapeutique contre des maladies hépatiques | |
EP3947390A4 (fr) | Compositions et leurs méthode d'utilisation pour le traitement d'une maladie neurodegenerative et mitochondriale | |
EP3634394A4 (fr) | Compositions pour le traitement de maladies neurodégénératives | |
EP3619204A4 (fr) | Composés pour traiter des maladies respiratoires | |
GB201805100D0 (en) | Treatment of sarcopenic diseases | |
GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
IL273929A (en) | Therapeutic agents for neurodegenerative diseases | |
EP3862012A4 (fr) | Agent thérapeutique pour maladie neurodégénérative | |
EP3897602A4 (fr) | Associations pharmaceutiques pour le traitement du cancer | |
EP3283457A4 (fr) | Composés et procédés pour le traitement de maladies neurodégénératives | |
EP3761982A4 (fr) | Traitement de maladies démyélinisantes | |
EP3706867A4 (fr) | Polythérapies pour le traitement de l'ataxie cérébelleuse | |
EP3846816A4 (fr) | Agents neuroprotecteurs pour le traitement de maladies neurodégénératives | |
EP3672583A4 (fr) | Compositions et méthodes pour traiter des maladies neurodégénératives | |
EP3534954A4 (fr) | Composés pour le traitement de maladies neurodégénératives | |
EP3755334A4 (fr) | Traitement de maladies hépatiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210308 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/16 20060101ALI20220408BHEP Ipc: A61P 25/28 20060101ALI20220408BHEP Ipc: A61K 31/4184 20060101ALI20220408BHEP Ipc: A61K 31/137 20060101ALI20220408BHEP Ipc: A61K 31/428 20060101ALI20220408BHEP Ipc: A61K 31/496 20060101ALI20220408BHEP Ipc: A61K 31/495 20060101AFI20220408BHEP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0031497000 Ipc: A61K0031495000 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220715 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/16 20060101ALI20220711BHEP Ipc: A61P 25/28 20060101ALI20220711BHEP Ipc: A61K 31/4184 20060101ALI20220711BHEP Ipc: A61K 31/137 20060101ALI20220711BHEP Ipc: A61K 31/428 20060101ALI20220711BHEP Ipc: A61K 31/496 20060101ALI20220711BHEP Ipc: A61K 31/495 20060101AFI20220711BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240514 |